Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Day One Biopharmaceuticals (DAWN) Return on Capital Employed (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Return on Capital Employed for 4 consecutive years, with 0.28% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 14.0% to 0.28% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.28%, a 14.0% increase, with the full-year FY2025 number at 0.26%, up 27.0% from a year prior.
  • Return on Capital Employed was 0.28% for Q4 2025 at Day One Biopharmaceuticals, up from 0.36% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.24% in Q2 2025 to a low of 1.08% in Q2 2024.
  • A 4-year average of 0.49% and a median of 0.46% in 2024 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: tumbled -59bps in 2024, then surged 85bps in 2025.
  • Day One Biopharmaceuticals' Return on Capital Employed stood at 0.42% in 2022, then crashed by -34bps to 0.56% in 2023, then rose by 26bps to 0.42% in 2024, then skyrocketed by 32bps to 0.28% in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Return on Capital Employed are 0.28% (Q4 2025), 0.36% (Q3 2025), and 0.24% (Q2 2025).